FR23C1005I1 - Vaccins contre les flavivirus - Google Patents

Vaccins contre les flavivirus

Info

Publication number
FR23C1005I1
FR23C1005I1 FR23C1005C FR23C1005C FR23C1005I1 FR 23C1005 I1 FR23C1005 I1 FR 23C1005I1 FR 23C1005 C FR23C1005 C FR 23C1005C FR 23C1005 C FR23C1005 C FR 23C1005C FR 23C1005 I1 FR23C1005 I1 FR 23C1005I1
Authority
FR
France
Prior art keywords
vaccines against
against flavivirus
flavivirus
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1005C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29739394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1005(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of FR23C1005I1 publication Critical patent/FR23C1005I1/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FR23C1005C 2002-01-15 2023-01-12 Vaccins contre les flavivirus Active FR23C1005I1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34894902P 2002-01-15 2002-01-15
US38528102P 2002-05-31 2002-05-31
EP10013094A EP2295023A1 (en) 2002-01-15 2003-01-15 Flavivirus vaccines
PCT/US2003/001214 WO2003103571A2 (en) 2002-01-15 2003-01-15 Flavivirus vaccines
EP03748884A EP1471873A4 (en) 2002-01-15 2003-01-15 VACCINES AGAINST FLAVIVIRUS

Publications (1)

Publication Number Publication Date
FR23C1005I1 true FR23C1005I1 (fr) 2023-03-24

Family

ID=29739394

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1005C Active FR23C1005I1 (fr) 2002-01-15 2023-01-12 Vaccins contre les flavivirus

Country Status (14)

Country Link
US (5) US7459160B2 (ko)
EP (3) EP3679915B1 (ko)
JP (2) JP2005519639A (ko)
KR (2) KR101194818B1 (ko)
CN (1) CN103555669B (ko)
AU (1) AU2003267937C1 (ko)
BR (3) BRPI0306905B8 (ko)
CA (1) CA2473321C (ko)
ES (1) ES2924640T3 (ko)
FR (1) FR23C1005I1 (ko)
IL (3) IL163001A (ko)
MX (1) MXPA04006870A (ko)
NZ (1) NZ534159A (ko)
WO (1) WO2003103571A2 (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
KR100921592B1 (ko) 2001-06-01 2009-10-14 사노피 파스테르 바이오로직스 씨오 키메라 플라비바이러스 벡터
BRPI0306905B8 (pt) 2002-01-15 2021-05-25 Acambis Inc método de produção de uma composição imunogênica/dengue que compreende um flavivírus
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
ES2337893T3 (es) 2002-11-15 2010-04-30 Sanofi Pasteur Biologics Co. Vacuna del virus del nilo occidental.
CA2582534A1 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
US8124398B2 (en) 2005-04-24 2012-02-28 Sanofi Pasteur Biologics Co. Recombinant flavivirus vaccines
AU2013204985B2 (en) * 2005-04-24 2016-01-28 Sanofi Pasteur Biologics, Llc Recombinant flavivirus vaccines
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
EP2535058A3 (en) 2006-11-07 2013-04-10 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
BRPI0909820A2 (pt) 2008-03-05 2015-08-11 Sanofi Pasteur Processo para estabilização de composição de vacina contra gripe, para estabilização de composição de vacina contendo adjuvante e para preparação de vacina, composições de vacina, kit de vacina e método de estocagem de uma matéria prima
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
EP2550292B1 (en) * 2010-03-24 2017-11-22 Research Development Foundation Flavivirus host range mutations and uses thereof
US8889148B2 (en) 2010-07-01 2014-11-18 Research Development Foundation Flavivirus host-range mutations and uses thereof
EP3932422A1 (en) * 2012-07-24 2022-01-05 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
MY187896A (en) 2013-06-21 2021-10-27 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
TW201620546A (zh) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
MY192543A (en) 2014-12-22 2022-08-26 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
WO2017005652A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US20180229407A1 (en) * 2017-02-03 2018-08-16 Marhaygue, Llc Structural Composition and Method
AU2018346724A1 (en) 2017-10-05 2020-05-14 Sanofi Pasteur Compositions for booster vaccination against dengu
AU2018388102A1 (en) 2017-12-21 2020-07-16 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
KR102269663B1 (ko) 2018-04-27 2021-06-28 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
AU2021364852A1 (en) * 2020-10-23 2023-06-22 Sk Bioscience Co., Ltd. Vaccine composition or kit for reducing size or volume of target tissue, containing genetic material that encodes foreign antigen
WO2023204693A1 (ko) * 2022-04-22 2023-10-26 에스케이바이오사이언스 주식회사 타겟 조직의 크기 또는 부피 축소용 조성물 또는 이를 포함하는 키트

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173418A (en) 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
DE69230316T2 (de) 1991-09-19 2000-07-13 Us Health Chimäre und/oder wachstumsgehemmte flaviviren
US6136561A (en) * 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
US6171864B1 (en) * 1996-07-05 2001-01-09 Pioneer Hi-Bred International, Inc. Calreticulin genes and promoter regions and uses thereof
EP0977587B1 (en) * 1997-02-28 2005-06-15 Acambis Inc. Chimeric flavivirus vaccines
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6416763B1 (en) * 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
AU1813901A (en) * 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
ES2395991T3 (es) * 1999-12-03 2013-02-18 Baxter International Inc. Ensayo de pirogenicidad para su uso con sistemas de inmunoensayo automáticos
ATE526411T1 (de) 2000-02-16 2011-10-15 Us Gov Health & Human Serv Avirulente, immunogene flavivirus-chimäre
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
KR100921592B1 (ko) 2001-06-01 2009-10-14 사노피 파스테르 바이오로직스 씨오 키메라 플라비바이러스 벡터
US6682883B1 (en) * 2001-07-19 2004-01-27 Acambis, Inc. Diagnosis of flavivirus infection
NZ532385A (en) * 2001-10-19 2007-01-26 Acambis Inc Methods of preventing and treating flavivirus infection in animals
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
BRPI0306905B8 (pt) 2002-01-15 2021-05-25 Acambis Inc método de produção de uma composição imunogênica/dengue que compreende um flavivírus
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
ES2337893T3 (es) 2002-11-15 2010-04-30 Sanofi Pasteur Biologics Co. Vacuna del virus del nilo occidental.
US7189403B2 (en) * 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
WO2005040390A1 (fr) 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. Vaccin recombine utilisant le virus de la fievre jaune comme vecteur
WO2005049815A1 (en) 2003-11-21 2005-06-02 K.U.Leuven Research & Development Flavivirus replication
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
US8124398B2 (en) 2005-04-24 2012-02-28 Sanofi Pasteur Biologics Co. Recombinant flavivirus vaccines
AU2006257610B2 (en) 2005-06-17 2012-11-15 Centers For Disease Control And Prevention Dengue serotype 1 attenuated strain
BRPI0504945B8 (pt) 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.
CN203286821U (zh) 2013-05-03 2013-11-13 珠海格力电器股份有限公司 双级增焓空调系统

Also Published As

Publication number Publication date
WO2003103571A2 (en) 2003-12-18
IL223457A (en) 2017-07-31
US20090191240A1 (en) 2009-07-30
EP1471873A2 (en) 2004-11-03
KR101074175B1 (ko) 2011-10-14
AU2003267937B2 (en) 2008-09-18
MXPA04006870A (es) 2005-05-16
WO2003103571A3 (en) 2004-04-22
BR122018075729B1 (pt) 2020-02-11
EP3679915B1 (en) 2022-06-01
US20130189306A1 (en) 2013-07-25
BRPI0306905B1 (pt) 2019-05-07
BR122018075729B8 (pt) 2021-07-27
IL223457A0 (en) 2013-02-03
IL223458A0 (en) 2013-02-03
JP2005519639A (ja) 2005-07-07
KR20040078666A (ko) 2004-09-10
EP1471873A4 (en) 2005-03-16
AU2003267937C1 (en) 2019-08-08
US10172929B2 (en) 2019-01-08
JP2010268804A (ja) 2010-12-02
US7459160B2 (en) 2008-12-02
ES2924640T3 (es) 2022-10-10
JP5554646B2 (ja) 2014-07-23
US8852914B2 (en) 2014-10-07
CN103555669B (zh) 2017-10-13
KR20110013494A (ko) 2011-02-09
EP2295023A1 (en) 2011-03-16
CN103555669A (zh) 2014-02-05
KR101194818B1 (ko) 2012-10-25
BRPI0306905B8 (pt) 2021-05-25
US20150024004A1 (en) 2015-01-22
US20080274142A1 (en) 2008-11-06
IL163001A (en) 2012-12-31
US20190192649A1 (en) 2019-06-27
NZ534159A (en) 2007-03-30
CA2473321C (en) 2015-10-06
EP3679915A1 (en) 2020-07-15
AU2003267937A1 (en) 2003-12-22
BR0306905A (pt) 2005-04-12
CA2473321A1 (en) 2003-12-18
BR122018075730B1 (pt) 2022-04-19

Similar Documents

Publication Publication Date Title
FR23C1005I1 (fr) Vaccins contre les flavivirus
MA28609B1 (fr) Vaccins
IL177667A0 (en) Flavivirus vaccines
MA28639B1 (fr) Vaccins
EP1804831A4 (en) VACCINES BASED ON LLO AND LISTERIA
MA28885B1 (fr) vaccins
IL173921A0 (en) Vaccine
GB0329146D0 (en) Vaccine
GB0212046D0 (en) Vaccines
GB0323840D0 (en) Vaccines
GB0305794D0 (en) Vaccine
GB0328753D0 (en) Hepatitis B vaccines
GB0330079D0 (en) Vaccine
GB0321614D0 (en) Vaccines
GB0305793D0 (en) Vaccine
GB0304634D0 (en) Vaccines
TWI350174B (en) Adjuvanted bovine vaccines
GB0212036D0 (en) Vaccines
GB0308691D0 (en) Vaccine preparations
GB0412407D0 (en) Vaccine
GB0406598D0 (en) Vaccine
GB0330007D0 (en) Vaccines
GB0304672D0 (en) Vaccines
GB0300914D0 (en) Vaccines
GB0300397D0 (en) Vaccines